Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS withdraws Ixempra in Europe

Executive Summary

Bristol-Myers Squibb has withdrawn its application to market Ixempra (ixabepilone) in Europe, the European Medicines Agency announced March 19. The metastatic breast cancer drug gained U.S. approval for a fourth-line indication as monotherapy in a salvage setting, and as third-line combination therapy based on progression-free survival - an endpoint that FDA was concerned would not translate to overall survival benefit, according to agency review documents (1Pharmaceutical Approvals Monthly, June 1, 2008, p. 36). In Europe, Ixempra was proposed for in combination with capecitabine to treat locally advanced or metastatic breast cancer after failure of previous cytotoxic chemotherapy treatments. It had received a negative opinion from CHMP

You may also be interested in...



FDA Cleared Ixempra Despite Doubts Over Chance Of Showing Survival Benefit

Doubts about the likelihood that the improvement in progression-free survival seen in a pivotal trial of Bristol-Myers Squibb's Ixempra (ixabepilone) will translate to an overall survival advantage could add to the controversy over the appropriateness of PFS as a surrogate for survival in metastatic breast cancer.

Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’

Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.

US Meeting Set For CBDs’ Impact On Pregnancies, Gender-Specific Biological, Psychosocial Effects

FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel